Drug companies get better marks on public disclosure

Drug companies are making more information public about medical studies they are conducting, but some still withhold key details, a new analysis of a federal registry finds.

Merck & Co., stung by allegations that it hid information on Vioxx's dangers, gets somewhat better marks in the new analysis than it did in an earlier one. However, Pfizer Inc., GlaxoSmithKline PLC and Novartis AG are lagging, according to the report in today's New England Journal of Medicine.